5,215 Shares in Gilead Sciences, Inc. (GILD) Acquired by Surevest Inc.

Surevest Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,215 shares of the biopharmaceutical company’s stock, valued at approximately $326,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. Athena Capital Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $27,000. Capital Financial Planning LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $27,000. Advisors Preferred LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $31,000. Legacy Financial Advisors Inc. raised its position in shares of Gilead Sciences by 361.3% in the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 383 shares during the last quarter. Finally, Claybrook Capital LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $32,000. Institutional investors own 80.21% of the company’s stock.

In other news, Director Gayle E. Wilson sold 19,068 shares of Gilead Sciences stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the transaction, the director now directly owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,802 shares of company stock worth $2,956,422. 0.20% of the stock is owned by corporate insiders.

GILD has been the subject of a number of analyst reports. Maxim Group set a $84.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, February 5th. Raymond James set a $90.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, February 5th. Citigroup reissued a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a report on Tuesday, February 5th. Mizuho reissued a “buy” rating and issued a $88.00 price objective on shares of Gilead Sciences in a report on Tuesday, February 26th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Gilead Sciences in a report on Thursday, March 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $80.94.

Shares of NASDAQ:GILD opened at $65.15 on Friday. The company has a market capitalization of $83.06 billion, a P/E ratio of 10.59, a PEG ratio of 4.15 and a beta of 1.16. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period last year, the business earned $1.78 EPS. The firm’s revenue was down 2.6% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 6.3 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $2.52 dividend on an annualized basis and a yield of 3.87%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/27/surevest-inc-invests-326000-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.